We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Duplex ddPCR Assay Evaluated for Salmonella and Shigella

By LabMedica International staff writers
Posted on 28 Apr 2022
Print article
Image: The Bio-Rad QX200 Droplet Digital PCR (ddPCR) System provides absolute quantification of target DNA or RNA molecules for EvaGreen or probe-based digital PCR applications (Photo courtesy of Bio-Rad)
Image: The Bio-Rad QX200 Droplet Digital PCR (ddPCR) System provides absolute quantification of target DNA or RNA molecules for EvaGreen or probe-based digital PCR applications (Photo courtesy of Bio-Rad)

Bacteria of the genus Salmonella and Shigella are important pathogens of infectious diarrhea. Salmonellosis was the second most commonly reported gastrointestinal infection in humans in the European Union in 2018. Shigella spp was the second leading cause of mortality caused by diarrhea among all ages in 2016 globally, accounting for 212,438 deaths.

Various nucleic acid detection techniques have been widely used in screening diarrheal pathogens. Quantitative real-time PCR (qPCR) is one of the most commonly used techniques in this regard, and the quantification cycle (Cq) of qPCR is predictive of the quantity of input target. A duplex droplet digital PCR (ddPCR) assay targeting Salmonella fimY and Shigella ipaH genes has been evaluated.

Infectious Disease Specialists at the Chinese Center for Disease Control and Prevention (Beijing, China) and their colleagues analyzed 362 stool samples by the duplex ddPCR and the singleplex qPCR assays, including 187 diarrheal and 175 non-diarrheal samples. They first conducted a pilot study with 52 characterized stool samples (36 diarrheal and 16 non-diarrheal) collected from Shanghai, which had been tested for Salmonella spp and Shigella spp by traditional culture methods. The ddPCR was performed on a QX200 ddPCR system (Bio-Rad Laboratories, Hercules, CA, USA). For the singleplex qPCR assays amplification and detection were performed with a LightCycler 96 system (Roche, Indianapolis, IN, USA).

The scientists reported that the duplex ddPCR assay showed good linearity in the range of 5.3 × 100 to 1.24 × 105 copies/reaction for Salmonella and 1.9 × 100 to 1.84 × 105 copies/reaction for Shigella. When analyzed with spiked stool samples, the limit of detection and limit of quantification were 550 and 5,500 CFU/mL stool sample for Shigella, respectively; while both were 1.0 × 104 CFU/mL stool sample for Salmonella. Among 362 stool samples, more samples were detected as positive by ddPCR than by qPCR. Salmonella load was significantly higher in the diarrheal samples than in the non-diarrheal samples. Determined by receiver-operating characteristic analysis, the optimal cut-off value was 1.25 × 104 copies/mL stool sample to distinguish between symptomatic and asymptomatic Salmonella infections.

The authors concluded that ddPCR detected more Salmonella and Shigella infections and that the prevalence of these two bacteria may have been underestimated in the past. The study was published on April 23, 2022 in the International Journal of Infectious Diseases.

Related Links:
Chinese Center for Disease Control and Prevention 
Bio-Rad Laboratories 
Roche 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.